The sustained efficacy and safety data through two years strengthen the case for regulatory submission in achondroplasia. Monitor for upcoming FDA/EMA filing announcements and potential partnership or commercialization updates. The stock may see positive momentum as the data derisk the program.
ASND drugs
ASND drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $267.79entry
- T+1 · 5mo ago +2.51%α +2.64% · $274.50
- T+5 · 4mo ago −0.31%α −0.57% · $266.97
- T+20 · 4mo ago −5.88%α −3.69% · $252.05
- T+60 · 8w ago −13.85%α −16.81% · $230.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma announced Week 104 radiographic data from the pivotal ApproaCH trial of TransCon CNP (navepegritide) in achondroplasia, showing continued improvements in lower extremity alignment (tibial-femoral angle) through two years with a favorable safety profile. The data reinforce the drug's disease-modifying potential and support regulatory advancement.
Key Facts
- TransCon CNP-treated children showed mean TFA improvement of -2.2 degrees over two years (baseline 9.1° to 6.9° at Week 104).
- In children with baseline TFA ≥5° (genu varum), mean TFA improved -3.8 degrees over two years (13.4° to 9.6°).
- Placebo-switch group showed TFA improvement of -1.7 degrees during the 52-week open-label extension.
- Mean TFA Z-score decreased from 3.62 at baseline to 2.96 at Week 104 in the continuous-treatment group.
- No symptomatic hypotension, no acceleration of bone age, and no treatment discontinuations due to adverse events.
- Data presented at the 12th International Conference on Children's Bone Health (ICCBH 2026) in Montreal.
Financial Impact
No financial data in filing; positive clinical data supports TransCon CNP's regulatory and commercial prospects in achondroplasia, a market with limited approved therapies.
Risk Factors
- Competition from BioMarin's Voxzogo (vosoritide) already approved for achondroplasia.
- Regulatory timelines and potential requirements for additional clinical data.
- Commercial adoption dependent on pricing, reimbursement, and physician preference.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-290485 |
| Document: 0001193125-26-290485-index-headers.html | 0001193125-26-290485 |
| Document: 0001193125-26-290485-index.html | 0001193125-26-290485 |
| Document: 0001193125-26-290485.txt | 0001193125-26-290485 |
Track record
41 reports on ASND
14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers